A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

NCT02589665 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

249

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Mirikizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company